Table 1.
Oxidative oxLDL test | Population under study | CV endpoints | Number of events | Followup | Findings | Reference |
---|---|---|---|---|---|---|
OxLDL Abs 4E06 | 326 men | IMT | na | 3 years | OxLDL predicted IMT and carotid plaque progression | Wallenfeldt et al. [88] |
| ||||||
OxLDL Abs 4E06 | 765 subjects | CV events | 77 CV events | 5 years | OxLDL predicted CV events | Tsimikas et al. [90] |
| ||||||
OxLDL Abs 4E06 | 765 subjects | CV events | 82 CV events | 10 years | OxLDL predicted CV events | Kiechl et al. [92] |
| ||||||
OxPL/apoB, AutoAbs MDA-/Cu-oxLDL | 765 subjects | CV events | 138 CV events | 15 years | OxPL/apoB predicted CV events and stroke; AutoAbs predicted CV events, stroke, and ACS | Tsimikas et al. [94] |
| ||||||
MDA-LDL | 907 NIDDM | CV events, MI | 152 CV events, 43 MI | 3.7 years | MDA-LDL predicted MI and CV events | Lopes-Virella et al. [93] |
| ||||||
AutoAbs Cu-oxLDL | 249 ESRD | CV mortality | 74 CV deaths | 63 months | AutoAbs predicted CV mortality | Shoji et al. [84] |
| ||||||
AutoAbs Cu-oxLDL | 94 ESRD on hemodialysis | Total mortality | 32 deaths | 24 months | AutoAbs predicted mortality | Bays et al. [85] |
| ||||||
AutoAbs Cu-oxLDL | 94 ESRD on hemodialysis | CV mortality | 33 CV deaths | 4 years | AutoAbs predicted CV mortality | Bays et al. [86] |
| ||||||
OxLDL Abs DLH3 | 246 pts with coronary angiography | CV events: cardiac death, MI, PTCA, and CABG | 76 CV events | 38 months | OxLDL predicted CV events | Shimada et al. [87] |
| ||||||
AutoAbs MDA-oxLDL | 734 IHD pts | CV mortality, MI, ACS, and CV events | 65 CV deaths, 153 CV events | 7.2 years | OxLDL predicted CV death and events | Maiolino et al. [81] |
| ||||||
AutoAbs Cu-oxLDL | 74 PTCA pts, 14 ctr | Restenosis | 34 restenosis | 6 months | AutoAbs predicted restenosis | Lee et al. [107] |
| ||||||
OxLDL Abs DLH3 | 102 primary PTCA pts, 86 ctr | Restenosis | 25 restenosis | 6 months | OxLDL predicted restenosis | Naruko et al. [89] |
| ||||||
OxLDL Abs 4E06 | 433 ACS pts | CV death, MI | 17 CV deaths, 57 MI | 2 years | OxLDL predicted MI | Johnston et al. [91] |
| ||||||
OxLDL Abs FOH1a/DLH3 | 84 CHF pts (EF < 45%), 18 ctr | CV death, CV hospitalization, and fatal arrhythmia | 26 CV events | 780 days | OxLDL predicted CV events | Tsutsui et al. [83] |
Abs: antibodies; ACS: acute coronary syndrome; AutoAbs: autoantibodies; CABG: coronary artery by-pass surgery; CHF: congestive heart failure; Crt: controls; CV: cardiovascular; ESRD: end-stage renal disease; IHD: ischemic heart disease; IMT: intima-media thickness; MI: myocardial infarction; oxLDL: oxidized low-density lipoproteins; OxPL/apoB: oxidized phospholipids on apolipoprotein B-100; PTCA: percutaneous transluminal coronary angioplasty; pts: patients.